ONECUT2 and renal pelvis/ureter urothelial carcinoma: Surprisingly, this is the first time that the superiority of this epigenetic biomarker ONECUT2 has been demonstrated in UTUC diagnostic studies, and reported a high potential for clinical application compared to other methylation related methods.